Featuring perspectives from Dr Aditya Bardia, Prof Giuseppe Curigliano, Dr Hope S Rugo and Dr Antonio C Wolff, including the following topics:

• Introduction (0:00)
• Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer — Dr Wolff (2:28)
• Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr Bardia (23:16)
• Practical Applications of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Metastatic Breast Cancer — Prof Curigliano (51:31)
• Future Directions for HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Breast Cancer — Dr Rugo (1:11:57)

CME information and select publications

Featuring perspectives from Dr Sagar Lonial, Prof Philippe Moreau, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:

• Introduction (0:00)
• Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski (1:26)
• Integration of Novel Therapies into the Management of Relapsed/Refractory MM — Dr Richardson (26:53)
• Chimeric Antigen Receptor T-Cell Therapy for MM — Dr Raje (48:48)
• Bispecific Antibodies for the Treatment of MM — Prof Moreau (1:12:52)
• Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial (1:36:32)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics:

• Introduction (0:00)
• Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44)
• Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43)
• Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20)
• Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06)

CME information and select publications

Featuring perspectives from Dr Christopher Lieu, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Daneng Li, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen “Fred” Divers

CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics:

• Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment
  • Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00)
• EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer
  • Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50)
• Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer
  • Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43)

CME information and select publications